Mithramycin induces fetal hemoglobin production in normal and thalassemic human erythroid precursor cells

Blood

Volumn 102, Issue 4, 2003, Pages 1276-1281

  Fibach, Eitan ^b   Bianchi, Nicoletta ^b   Borgatti, Monica ^b   Prus, Eugenia ^b   Gambari, Roberto ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GLOBIN; BETA ACTIN; BETA GLOBIN; ERYTHROPOIETIN; GAMMA GLOBIN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HEMOGLOBIN F; HYDROXYUREA; MESSENGER RNA; MITHRAMYCIN;

ARTICLE; BETA THALASSEMIA; BLOOD; CELL CULTURE; CELL DIFFERENTIATION; CELL GROWTH; CELL LEVEL; CELL MATURATION; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG DNA BINDING; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; ERYTHROBLAST; ERYTHROID PRECURSOR CELL; FLOW CYTOMETRY; HEMOGLOBIN SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIQUID CULTURE; MEASUREMENT; PRIORITY JOURNAL; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEM CELL; UPREGULATION;

EID: 0043240257     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-10-3096     Document Type: Article

References (53)

1. Rodgers GP, Rachmilewitz EA. Novel treatment options in the severe β-globin disorder. Br J Haematol. 1995;91:263-268.
2. Rochette J, Craig JE, Thein SL. Fetal hemoglobin levels in adults. Blood Rev. 1994;8:213-224.
3. Olivieri NF, Weatherall DJ. The therapeutic reactivation of fetal hemoglobin. Hum Mol Genet. 1998; 7:1655-1658.
4. Olivieri NF, Reee DC, Ginder DG, et al. Elimination of transfusions through induction of fetal hemoglobin synthesis in Cooley's anemia. Ann N Y Acad Sci. 1998;850:100-109.
5. Swank RA, Stamatoyannopoulos G. Fetal gene reactivation. Curr Opin Genet Dev. 1998;8:366-370.
6. Saleh AW, Hillen HF. Pharmacological induction of foetal haemoglobin synthesis in sickle-cell disease. Neth J Med. 1997;51:169-178.
7. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicente Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med. 1995;332:1317-1322.
8. Steinberg MH, Lu ZH, Barton FB, Terrin ML, Charache S, Dover GJ. Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Multicenter Study of Hydroxyurea. Blood. 1997;89:1078-1088.
9. Dover GJ, Brusilow S, Samid D. Increased fetal hemoglobin in patients receiving sodium 4-phenylbutyrate. N Engl J Med. 1992;327:569-570.
10. Fibach E, Prasanna P, Rodgers GP, Samid D. Enhanced fetal hemoglobin production by phenylacetate and 4-phenylbutyrate in erythroid precursors derived from normal donors and patients with sickle cell anemia and beta-thalassemia. Blood. 1993;82:2203-2209.
11. Rodgers GP, Dover GJ, Uyesaka N, Noguchi CT, Schechter AN, Nienhuis AW. Augmentation by erythropoietin of the fetal-hemoglobin response to hydroxyurea in sickle cell disease. N Engl J Med. 1993;328:73-80.
12. Ikuta T, Atweh G, Boosalis V, et al. Cellular and molecular effects of a pulse butyrate regimen and new inducers of globin gene expression and hematopoiesis. Ann N Y Acad Sci. 1998;850:87-99.
13. Perrine SP, Ginder GD, Faller DV, et al. A short-term trial of butyrate to stimulate fetal-globin-gene expression in the beta-globin disorders. N Engl J Med. 1993;328:81-86.
14. Bianchi N, Osti F, Rutigliano C, et al. The DNA-binding drugs mithramycin and chromomycin are powerful inducers of erythroid differentiation of human K562 cells. Br J Haematol. 1999;104:258-265.
15. Bianchi N, Ongaro F, Chiarabelli C, et al. Induction of erythroid differentiation of human K562 cells by cisplatin analogs. Biochem Pharmacol. 2000;60:31-40.
16. Dervan PB. Design of sequence-specific DNA binding molecules. Science. 1986;232:464-471.
17. Bianchi N, Passadore M, Feriotto G, Mischiati C, Gambari R, Piva R, Alteration of the expression of human estrogen receptor gene by distamycin. J Steroid Biochem Mol Biol. 1995;54:211-215.
18. Bianchi N, Passadore M, Rutigliano C, Feriotto G, Mischiati C, Gambari R. Targeting of the Sp1 binding sites of HIV-1 long terminal repeat with chromomycin. Disruption of nuclear factor. DNA complexes and inhibition of in vitro transcription. Biochem Pharmacol. 1996;52:1489-1498.
19. Vaquero A, Portugal J. Modulation of DNA-protein interactions in the P1 and P2 c-myc promoters by two intercalating drugs. Eur J Biochem. 1998; 251:435-442.
20. Ray R, Snyder RC, Thomas S, Koller CA, Miller DM. Mithramycin blocks protein binding and function of the SV40 early promoter. J Clin Invest. 1989;83:2003-2007.
21. Snyder RC, Ray R, Blume S, Miller DM. Mithramycin blocks transcriptional initiation of the c-myc P1 and P2 promoters. Biochemistry. 1991;30: 4290-4297.
22. Welch JJ, Rauscher FJ III, Beerman TA. Targeting DNA-binding drugs to sequence-specific transcription factor. DNA complexes. Differential effects of intercalating and minor groove binding drugs. J Biol Chem. 1994;269:31051-31058.
23. Gambari R, Feriotto G, Rutigliano C, Bianchi N, Mischiati C. Biospecific interaction analysis (BIA) of low-molecular weight DNA-binding drugs. J Pharmacol Exp Ther. 2000;294:370-377.
24. Singh B, Gupta RS. Species-specific differences in the toxicity and mutagenicity of the anticancer drugs mithramycin, chromomycin A3, and olivomycin. Cancer Res. 1985;45:2813-2820.
25. Dutcher JP, Coletti D, Paietta E, Wiernik PH. A pilot study of alpha-interferon and plicamycin for accelerated phase of chronic myeloid leukemia. Leuk Res. 1997;21:375-380.
26. Hadjipavlou AG, Gaitanis LN, Katonis PG, Lander P. Paget's disease of the spine and its management. Eur Spine J. 2001;10:370-384.
27. Zojer N, Keck AV, Pecherstorfer M. Comparative tolerability of drug therapies for hypercalcaemia of malignancy. Drug Saf. 1999;21:389-406.
28. Esbrit P, Hurtado J. Treatment of malignant hypercalcaemia. Expert Opin Pharmacother. 2002; 3:521-527.
29. Cioè L, McNab A, Hubbell HR, Meo P, Curtis P, Rovera G. Differential expression of the globin genes in human leukemia K562(S) cells induced to differentiate by hemin or butyric acid. Cancer Res. 1981;41:237-243.
30. Fibach E, Manor D, Oppenheim A, Rachmilewitz EA. Proliferation and maturation of human erythroid progenitors in liquid medium. Blood. 1989; 73:100-103.
31. Fibach E, Manor D, Treves A, Rachmilewitz EA. Growth of human normal erythroid progenitors in liquid culture: a comparison with colony growth in semisolid culture. Int J Cell Cloning. 1991;9:57-64.
32. Fibach E. Cell culture and animal models to screen for promising fetal hemoglobin-stimulating compounds. Semin Hematol. 2001;38:374-381.
33. Fibach E. Techniques for studying stimulation of fetal hemoglobin production in human erythroid cultures. Hemoglobin. 1998;22:445-458.
34. Pope SH, Fibach E, Sun J, Chin K, Rodgers GP. Two-phase liquid culture system models normal human adult erythropoiesis at the molecular level. Eur J Haematol. 2000;64:292-303.
35. Huang SZ, Rodgers GP, Zeng FY, Zeng YT, Schechter AN. Diagnosis of thalassemia using cDNA amplification of circulating erythroid cell mRNA with the polymerase chain reaction. Blood. 1991;78:2433-2437.
36. Sambrook J, Fritsch EF, Maniatis T. Extraction, purification and analysis of messenger RNA from eukaryotic cells. In: Nolan C, ed. Molecular Cloning. 2nd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory; 1981;7.43-7.45.
37. Holland PM, Abramson RD, Watson R, Gelfand DH. Detection of specific polymerase chain reaction product by utilizing the 5′-3′ exonuclease activity of Thermus aquaticus DNA polymerase. Proc Natl Acad Sci U S A. 1991;88: 7276-7281.
38. Livak KJ, Flood SJ, Marmaro J, Giusti W, Deetz K. Oligonucleotides with fluorescent dyes at opposite ends provide a quenched probe system useful for detecting PCR product and nucleic acid hybridization. PCR Methods Appl. 1995;4:357-362.
39. Heid CA, Stevens J, Livak KJ, Williams PM. Real time quantitative PCR. Genome Res. 1996;6:986-994.
40. Gibson UE, Heid CA, Williams PM. A novel method for real time quantitative RT-PCR. Genome Res. 1996;6:995-1001.
41. Fibach E, Burke LP, Schechter AN, Noguchi CT, Rodgers GP. Hydroxyurea increases fetal hemoglobin in cultured erythroid cells derived from normal individuals and patients with sickle cell anemia or beta-thalassemia. Blood. 1993;81:1630-1635.
42. Mir MA, Dasgupta D. Interaction of antitumor drug, mithramycin, with chromatin. Biochem Biophys Res Commun. 2001;280:68-74.
43. Riggs CE. Antitumor antibiotics and related compounds. In: Perry MC, ed. The Chemotherapy Source Book. Baltimore, MD: Williams & Wilkins; 1992:340-342.
44. Green L, Donehower RC. Hepatic toxicity of low doses of mithramycin in hypercalcemia. Cancer Treat Rep. 1984;68:1379-1381.
45. Schaiff RA, Hall TG, Bar RS. Medical treatment of hypercalcemia. Clin Pharm. 1989;8:108-121.
46. Stapleton FB, Luker BP, Linshaw MA. Treatment of hypercalcemia associated with osseous metastases. J Pediatr. 1976;89:1029-1030.
47. Koller CA, Miller DM. Preliminary observations on the therapy of the myeloid blast phase of chronic granulocytic leukemia with plicamycin and hydroxyurea. N Engl J Med. 1986;315:1433-1438.
48. Fabricius E, Rajewsky F. Determination of hydroxyurea in mammalian tissues and blood. Rev Eur Etud Clin Biol. 1971;16:679-683.
49. Fang K, Koller CA, Brown N, Covington W, Lin JR, Ho DH. Determination of plicamycin in plasma by radioimmunoassay. Ther Drug Monit. 1992;14:255-260.
50. Fujiwara K, Saita T, Nakashima K, Kitagawa T. Enzyme immunoassay for the quantification of mithramycin using beta-D-galactosidase as a label. Cancer Res. 1986;46:1084-1088.
51. Pace BS, White GL, Dover GJ, Boosalis MS, Faller DV, Perrine SP. Short-chain fatty acid derivatives induce fetal globin expression and erythropoiesis in vivo. Blood. 2002;100:4640-4648.
52. Trefzer A, Blanco G, Remsing L, et al. Rationally designed glycosylated premithramycins: hybrid aromatic polyketides using genes from three different biosynthetic pathways. J Am Chem Soc. 2002;124:6056-6062.
53. Remsing LL, Garcia-Bernardo J, Gonzalez A, et al. Ketopremithramycins and ketomithramycins, four new aureolic acid-type compounds obtained upon inactivation of two genes involved in the biosynthesis of the deoxysugar moieties of the antitumor drug mithramycin by Streptomyces argillaceus, reveal novel insights into post-PKS tailoring steps of the mithramycin biosynthetic pathway. J Am Chem Soc. 2002;124:1606-1614.